J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction - a dose-response meta-analysis
Jufen Zhang,Aine Begley,Ruth Jackson,Michael C. Harrison,Pierpaolo Pellicori,Andrew L. Clark,John G.F. Cleland +6 more
TL;DR: For patients with heart failure, the relation between BMI and mortality is U-shaped with a similar nadir of risk for HFpEF and HFrEF at a BMI of 32–33 kg/m2.
Journal ArticleDOI
Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life
Tarek Bekfani,Pierpaolo Pellicori,Daniel A. Morris,Nicole Ebner,Miroslava Valentova,Miroslava Valentova,Anja Sandek,Wolfram Doehner,John G.F. Cleland,Mitja Lainscak,P. Christian Schulze,Stefan D. Anker,Stephan von Haehling,Stephan von Haehling +13 more
TL;DR: Iron deficiency is a frequent co-morbidity in HFpEF and is associated with reduced exercise capacity and QoL and its prevalence increases with increasing severity of diastolic dysfunction.
Journal ArticleDOI
Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis
Claire McKenna,Catriona McDaid,Sara Suekarran,Neil Hawkins,Karl Claxton,Kate Light,M Chester,John G.F. Cleland,Nerys Woolacott,Mark Sculpher +9 more
TL;DR: It is demonstrated that the long-term maintenance of quality of life benefits of EECP is central to the estimate of its cost-effectiveness, and the high risk of selection bias in all three studies was found.
Journal ArticleDOI
Developing New Treatments for Heart Failure: Focus on the Heart.
Mihai Gheorghiade,Christopher J. Larson,Sanjiv J. Shah,Stephen J. Greene,John G.F. Cleland,Wilson S. Colucci,Preston Dunnmon,Stephen E. Epstein,Raymond J. Kim,Ramin V. Parsey,Norman Stockbridge,James C. Carr,Wilfried Dinh,Thomas Krahn,Frank Kramer,Karin Wåhlander,Lawrence I. Deckelbaum,David Crandall,Shunichiro Okada,Michele Senni,Sergey Sikora,Hani N. Sabbah,Javed Butler +22 more
TL;DR: Drug development strategies should increasingly consider therapies that facilitate reverse remodeling by directly targeting the heart itself rather than strictly focusing on agents that unload the heart or target systemic neurohormones.
Structured Telephone Support or Telemonitoring Programs for Patients with Chronic Heart Failure (Protocol)
TL;DR: The objective of this study is to update the review previously completed by Clark 2007b and assess systematically the effects of telemonitoring and/or structured telephone support programmes on all cause mortality, CHF-related admission to hospital, all-cause readmissions to hospital and length of stay.